Circulation Research. 2006;98:868-878
doi: 10.1161/01.RES.0000216596.73005.3c
(Circulation Research. 2006;98:868.)
© 2006 American Heart Association, Inc.
ExcitationTranscription Coupling in Arterial Smooth Muscle
Brian R. Wamhoff,
Douglas K. Bowles,
Gary K. Owens
From Biomedical Sciences (D.K.B.), Veterinary School of Medicine, University of Missouri, Columbia, Mo; and the Department of Molecular Physiology and Biological Physics (B.R.W., G.K.O.), Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, Charlottesville, Va.
Correspondence to Gary K. Owens, Department of Molecular Physiology and Biological Physics, Robert M. Berne Cardiovascular Research Center, University of Virginia School of Medicine, PO Box 800736, Charlottesville, VA 22908-0736. E-mail gko{at}virginia.edu
This Review is part of a thematic series on New Paradigms of Transcriptional Control of Myocardial and Vascular Growth, which includes the following articles:
Redox-Dependent Transcriptional Regulation
Control of Cardiac Growth by Histone Acetylation/Deacetylation
ExcitationTranscription Coupling in Arterial Smooth Muscle
Gordon F. Tomaselli Editor
 |
Abstract
|
|---|
The primary function of the vascular smooth muscle cell (SMC)
is contraction for which SMCs express a selective repertoire
of genes (eg, SM

-actin, SM myosin heavy chain [SMMHC], myocardin)
that ultimately define the SMC from other muscle cell types.
Moreover, the SMC exhibits extensive phenotypic diversity and
plasticity, which play an important role during normal development,
repair of vascular injury, and in vascular disease states. Diverse
signals modulate ion channel activity in the sarcolemma of SMCs,
resulting in altered intracellular calcium (Ca) signaling, activation
of multiple intracellular signaling cascades, and SMC contraction
or relaxation, a process known as "excitationcontraction
coupling" (EC-coupling). Over the past 5 years, exciting new
studies have shown that the same signals that regulate EC-coupling
in SMCs are also capable of regulating SMC-selective gene expression
programs, a new paradigm coined "excitationtranscription
coupling" (ET-coupling). This article reviews recent progress
in our understanding of the mechanisms by which ET-coupling
selectively coordinates the expression of distinct gene subsets
in SMCs by disparate transcription factors, including CREB,
NFAT, and myocardin, via selective kinases. For example, L-type
voltage-gated Ca
2+ channels modulate SMC differentiation marker
gene expression, eg, SM

-actin and SMMHC, via Rho kinase and
myocardin and also regulate c-fos gene expression independently
via CaMK. In addition, we discuss the potential role of IK channels
and TRPC in ET-coupling as potential mediators of SMC phenotypic
modulation, ie, negatively regulate SMC differentiation marker
genes, in vascular disease.
Key Words: calcium ion channel sproliferation smooth muscle transcription
 |
Introduction
|
|---|
The vascular smooth muscle cell (SMC) in adult animals performs
a specialized form of contraction that requires expression of
a unique repertoire of genes, including SM

-actin, smooth muscle
myosin heavy chain (SMMHC), SM22

, calponin, desmin, and smoothelingenes
we refer to as SMC differentiation marker genes. This repertoire
of genes or "transcriptome" is typically used to describe the
"contractile" phenotype or mature SMC. There is clear evidence
that vascular SMCs are highly plastic and can alter the expression
profiles of SMC differentiation marker genes during development,
wound repair, and, in several disease states, a process termed
phenotypic modulation or switching (reviewed in Owens, Kumar,
and Wamhoff
1). For example, during early stages of vasculogenesis,
SMCs are highly migratory and undergo very rapid cell proliferation.
During vascular development, immature SMCs also exhibit very
high rates of synthesis of extracellular matrix components including
collagen, elastin, proteoglycans, cadherins, and integrins that
comprise a major portion of the blood vessel mass. In contrast,
in adult blood vessels the mature SMC shows an exceedingly low
rate of proliferation/turnover, is largely nonmigratory, shows
a very low rate of synthesis of extracellular matrix components,
and is primarily committed to performing its contractile function.
To this end, the mature, fully differentiated SMC expresses
a repertoire of appropriate receptors, ion channels, signal
transduction molecules, calcium regulatory proteins, and contractile
proteins necessary for the unique contractile properties of
the SMC. Importantly, different SMC subtypes express certain
common differentiation marker genes such as SM

-actin and SMMHC
and also unique genes that contribute to their specialized functional
properties and mechanisms of excitationcontraction (EC)
coupling.
24
The importance of SMC phenotypic switching and SMC plasticity for vascular repair undoubtedly has evolved in higher organisms because it conferred a survival advantage, although paradoxically these same properties likely contribute to disease susceptibility. For example, the plasticity of the SMC that enables it to rapidly undergo phenotypic switching in response to vessel injury also makes it susceptible to environmental cues that contribute to development of atherosclerosis, post-angioplasty restenosis, and other SMC-related diseases (see Owens et al1). It is also important to recognize that there is a continuous spectrum of SMC phenotype switching that can occur as a function of changing environmental cues. For example, after vascular injury, the SMC rapidly undergoes phenotypic modulation, which results in suppression of genes that define the quiescent/contractile phenotype, including SM
-actin, SMMHC, and SM22
while rapidly upregulating genes required for proliferation, including matrix metalloproteinases, and migration to lay down a new collagen matrix and repair the vessel wall. This response is required for vascular repair and is beneficial, assuming SMCs revert back to the more mature phenotype by re-inducing SMC differentiation marker genes once the injury/plaque has been stabilized. Unchecked, however, this response can often result in luminal narrowing neointimal hyperplasia that, in many contexts, can be detrimental. Thus, SMCs within adult mammals are highly plastic cells that are capable of rather profound alterations in their phenotype, ie, expression profiles of SMC differentiation marker genes, in response to changes in local environmental cues important for their differentiation and function.1
The purpose of this review is to highlight recent advancements in understanding how environmental cues that regulate EC-coupling are also involved in regulating SMC-selective gene expression and phenotypic modulation, mechanisms described herein as excitationtranscription (ET) coupling. We define ET-coupling as the process by which common signaling pathways that regulate EC-coupling also translate into transcriptional gene regulatory events in arterial smooth muscle. A particularly exciting aspect of ET-coupling is that it represents a potential integrative mechanism whereby short-term regulation of calcium signaling and contraction are transduced into long-term regulation of SMC growth, differentiation, and remodeling. We acknowledge that there are many different SMC subtypes, eg, arterial, venous, and visceral, and that EC-coupling varies depending on the function of each SMC subset. Moreover, whereas there are certainly critical differences in the transcriptome within different SMC subtypes, eg, including ion channels and receptors, there are also a very large number of common differentiation markers genes shared by all SMC subsets that are the central focus of the present review, including SM
-actin and smooth muscle myosin heavy chain.1,2 Thus, the next two sections of this review briefly review fundamental principles of EC-coupling and transcriptional regulation of SMC differentiation marker genes that are integral to our current knowledge of SMC ET-coupling in arterial SMCs. The final sections focus on specific mechanisms of ET-coupling that regulate arterial SMC gene expression and SMC phenotypic switching (Figure).

View larger version (29K):
[in this window]
[in a new window]
|
Excitation-transcription coupling in vascular smooth muscle. Proteins colored in green are proposed to favor activation of SMC differentiation marker expression (SMGX, eg, SMMHC) and the contractile phenotype, including: BK, large conductance Ca2+-activated K channels activated by "sparks;" VGCC, L-type voltage-gated Ca2+ channels; RhoA/ROK; Mycd, myocardin; SRF; p300, histone acetyltransferase; Ac, histone acetylation. Proteins colored in red are proposed to favor activation of proliferation or growth response gene expression (PLGX, eg, c-fos) and the synthetic phenotype, including: IKCa, intermediate conductance Ca2+-activated K channel; TRPC, canonical transient receptor potential channel involved in store-operated Ca2+ entry (SOCE); CaMK; CREB. The calcineurin (CaN)/NFAT axis is colored in black with dashed lines to indicate that the role of this axis in regulation SMC gene expression is unknown but clearly regulated in SMCs. X (gray) represents a yet undefined transcription factor that serves as a Ca2+-dependent suppressor of SMGX. The left side of cell depicts fluctuating changes in intracellular Ca2+ ([Ca2+]) over time (t). It is currently unknown how these short term changes in [Ca2+] are integrated into long-term changes in gene expression in arterial SMCs.
|
|
 |
EC-Coupling in SMCs: Sparks and SOCE
|
|---|
In vivo, arterial SMCs exist in a partially constricted state
in which the average intracellular Ca
2+ concentration is maintained
several orders of magnitude lower than the extracellular fluid,
eg,

100 to 300 nmol in pressurized microvessels.
5 Membrane potential,
through activation of voltage-gated Ca
2+ channels (VGCC), is
a primary determinant of myoplasmic Ca
2+ and vascular tone.
5 Due to the steep relationship between global myoplasmic Ca
2+ and vascular tone, myoplasmic Ca
2+, and thus membrane potential,
must be tightly regulated to maintain proper vascular resistance.
The underlying principle of EC-coupling in SMCs is that changes
in membrane potential affect actinmyosin interaction.
For example, depolarization-induced Ca
2+ influx through L-type
VGCC increases global myoplasmic Ca
2+ and activation of the
contractile apparatus both directly and via Ca
2+ release from
the sarcoplasmic reticulum (SR), ie, Ca
2+-induced Ca
2+ release
or CICR. Conversely, relaxation results from lowering global
myoplasmic Ca
2+ levels via hyperpolarization of the cell, primarily
by activation of K
+ channels, to limit Ca
2+ influx via VGCC
in combination with increased extrusion/uptake by the plasmalemmal
and endoplasmic Ca
2+ ATPases, respectively. In vivo, membrane
potential is determined by the net sum of all ionic conductances
across the cell membrane. Regulation of membrane potential in
arterial SMCs is further complicated by channel interactions,
for example, membrane depolarization and Ca
2+ influx directly
activate K
+ channels to limit depolarization, VGCC activation
and contraction in a negative feedback manner.
6 Furthermore,
intracellular Ca
2+ is not homogeneously distributed but rather
exhibits dynamic, spatially localized events such as Ca
2+ sparks,
puffs, and waves that are highly dependent on the intracellular
ultrastructure and the spatial relationship of various ion channels
and ion pumps on the SMC sarcolemma and sarcoplasmic reticulum.
4 In addition, Ca
2+ regulation varies with vessel caliber and
the nature of the vascular bed. Obviously, a comprehensive discussion
of each of these aspects of SMC Ca
2+ regulation in various SMC
subsets is beyond the scope of this review; therefore, we limit
our discussion to two concepts of Ca
2+ regulation that have
been shown to play a role in ET-coupling, Ca
2+ sparks and SOCE
(
Figure).
Sparks
Much of our knowledge of Ca2+ regulation in SMCs was derived from measures of global, averaged cytosolic Ca2+ levels. The emergence of high-resolution, high-speed Ca2+ imaging techniques in live SMCs, such as laser scanning confocal microscopy, has led to the realization that spatially localized Ca2+ signaling events play a major role in both EC- and ET-coupling in SMCs. Spatial and functional coupling of Ca2+ regulatory proteins and structures are critical to subcellular Ca2+ signaling. For example, tight spatial coupling (<100 nm in distance) between the superficial sarcoplasmic reticulum (junctional SR) and the sarcolemma produces a spatially and temporally discrete Ca2+ signaling complex. Spontaneous transient outward K+ currents (STOCs), first described by Benham and Bolton,7 are produced by activation of large-conductance, Ca2+-activated K+ (BKCa) channels by the spontaneous bolus release of Ca2+ from this junctional SR via ryanodine receptors (RyR). The first direct visualization of "Ca2+ sparks" in vascular SMCs was provided by Nelson and colleagues, demonstrating that a local increase in subsarcolemmal Ca2+, a Ca2+"spark," released by RyRs on the SR also activates BKCa channels in close proximity, producing membrane hyperpolarization and favoring relaxation.8 This concept has been expanded into a functional unit involving the L-type voltage-gated Ca2+ channel, BKCa channel and RyR.9 Downregulation of functional BKCa channels was shown to be associated with a decreased frequency of sparks in hypertension and disruption of the ß-subunit of BKCa resulted in hypertension.10 As discussed, the concept of sparks will prove critical in ET-coupling in SMCs and our understanding of how a SMC differentiates informational Ca2+ content required for EC-coupling from ET-coupling.
SOCE
Store-operated Ca2+ entry (SOCE), ie, capacitative Ca2+ entry (CCE), is yet another mechanism of EC-coupling and Ca2+ regulation that emphasizes tight Ca2+ regulation in the SMC through interaction with the SR. It has been shown in multiple cell types, including SMCs, that mitogen or growth factor depletion of the sarcoplasmic reticulum by IP3-mediated Ca2+ release results in the subsequent activation of transient receptor potential (TRP) cation channels that triggers Ca2+ entry into the cell, likely via TRPC.11 SOCE has been proposed to increase myoplasmic and nuclear Ca2+ required for the regulation of contraction,12 cell proliferation,13 and apoptosis. SOCE is also proposed to be responsible for replenishing Ca2+ within the SR. Although the gating of TRP channels and other voltage-independent channels are not altered by membrane potential per se, changes in membrane potential have a dramatic effect on the magnitude of Ca2+ flux through these channels by changing the electrochemical driving force for Ca2+ entry. For example, hyperpolarization due to activation of K+ channels displaces membrane potential (Vm) farther away from the equilibrium potential for Ca2+ (ECa), resulting in increased Ca2+ entry via TRP channels, whereas depolarization has the opposite effect. Thus, SMC excitation can significantly modulate Ca2+ entry through voltage-independent Ca2+ channels. However, the robustness and physiological relevance of SOCE in EC-coupling varies significantly with species, vascular bed, and phenotypic state of the SMC. For example, a standard protocol for determining SOCE is to deplete the SR with CPA or thapsigargin in the presence of an L-type VGCC blocker. When this approach was applied to intact pulmonary arterial rings, a contraction could be elicited and potentiated by overexpressing TRPC1.14 Regardless of the physiological relevance of TRPC/SOCE in contraction, there is evidence that SOCE plays a role in SMC proliferation as select TRPC isoforms are upregulated after mitogen-induced proliferation13,15 and after vascular injury in vitro.16 Thus, SOCE may play a critical role in ET-coupling and regulation of growth related genes in SMCs.
 |
Transcriptional Regulation of SMC Differentiation Marker Genes
|
|---|
To date, expression of the majority of SMC differentiation marker
genes that define the contractile SMC phenotype, including SM

-actin, SMMHC, SM22

, telokin, desmin, and h1-calponin, have
been shown to be dependent on at least one CArG element located
within the promoter-enhancer region of the gene.
1,17 Whereas
the transcriptomes of SMC subsets vary, ie, differential expression
of various ion channels and receptors, the CArG-dependent major
SMC marker genes that have been most thoroughly studied at the
transcriptional level are expressed in all SMC subtypes, a topic
recently reviewed by Yoshida and Owens.
2 The CArG element has
the general sequence motif of CC(A/T-rich)
6GG and binds serum
response factor (SRF), a MADS (MCM1, Agamous, Deficiens, SRF)
box transcription factor.
17 The general paradigm is that expression
of CArG-dependent SMC differentiation genes requires SRF binding
to CArG boxes to drive transcription. In vivo studies using
promoter-reporter constructs in transgenic mice have shown that
these CArG elements are required to recapitulate normal endogenous
gene expression patterns of SMMHC, SM

-actin, and SM22

.
1 The
CArG element was first identified in the promoter-enhancer region
of the early-immediate growth response gene, c-fos.
18 This presents
an interesting paradox for regulation of vascular SMC phenotype
in that the ubiquitous transcription factor, SRF, can stimulate
both SMC differentiation and growth. In this review, we discuss
differential regulation of SMC gene subsets in the context of
c-fos compared with CArG-dependent SMC differentiation markers,
eg, SM

-actin, SMMHC, SM22

, etc. Initial insight into this paradox
came from the observation that the c-fos promoter contains only
one CArG element, whereas as CArG-dependent SMC differentiation
markers, eg, SM

-actin, typically contain two CArGs in the promoter,
often with a single CArG in the first intronic region.
1 Moreover,
the SM

-actin CArGs have a single G or C substitution within
the central A/T-rich region of the CArG box, which substantially
lowers SRF binding affinity.
17 Our laboratory has provided evidence
that this degenerate SMC CArG box serves to limit SRF binding,
thereby restricting expression of SMC markers to cells that
express high levels of SRF and/or cells like SMCs that have
evolved mechanisms to enhance SRF binding to degenerate CArGs,
ie, a SMC-selective transcriptional SRF cofactor.
19,20
One of the most significant advances in the field of SMC differentiation in recent years was the discovery of myocardin by Olson and colleagues.21 Myocardin is exclusively expressed in cardiac myocytes and SMCs. It is a highly potent SRF coactivator that lacks intrinsic DNA binding activity but associates with SRF and stimulates CArG-dependent SMC differentiation marker gene expression up to several orders of magnitude.20,22 This activity is highly selective in that myocardin does not enhance activation of the c-fos gene, which is also CArG-SRFdependent. Conventional knockout of myocardin is associated with embryonic lethality at E10.5 days and failure to form SMCs.23 However, results of recent collaborative studies by our laboratory and that of Olson showed that autonomous myocardin is not absolutely required for SMC development, in that lacZ tagged homozygous KO embryonic stem cells (ESC) developed into SMCs in the context of chimeric KO mice generated by injection of myocardin null ESCs into the inner cell mass of blastocysts from wild-type C57bl6 mice.24 There is also evidence that interaction of myocardin with degenerate CArG elements within the promoter regions of SMC marker genes plays an important role in phenotypic switching of vascular SMC in vivo in response to vascular injury.19 Surprisingly, substitution of the SM
-actin degenerate CArG elements with c-fos CArG elements retained appropriate SMC-restricted tissue specificity.19 However, these substitutions prevented vascular injury-induced downregulation of the mutant transgene under conditions in which SRF was increased but myocardin was decreased. Thus, this illustrates the importance of the subtle, but highly conserved, base pair mutations in the SM
-actin CArG to SRF and myocardin-dependent regulation of SM
-actin during phenotypic switching in vivo.
Of interest, both regulation of SMC gene expression26,27 and SMC calcium sensitivity of contraction3 are regulated by the RhoA/ROK pathway. For example, the RhoA/ROK pathway has been shown to regulate the translocation of SRF from the cytosol to the nucleus in multiple cell types, including SMCs.28 Overexpression of the constitutively active form of RhoA stimulates transcription of SM
-actin, SM22
and SMMHC.27 In contrast, administration of the C3 transferase, which ADP ribosylates and irreversibly inhibits RhoA, or Y72632, a selective ROK inhibitor, decreased expression of multiple CArG-dependent SMC genes. Importantly, these effects were selective in that no effects were seen on the c-fos gene promoter that contains only one CArG element. The effects of RhoA have also been shown to be mediated through regulation of the actin cytoskeleton and specifically through alterations in the concentration of monomeric or G-actin.27 Treatment of SMCs with agents that increased formation of filamentous (F)-actin and decreased G-actin profoundly increased SMC gene transcription, whereas treatment with agents that increased G-actin markedly inhibited SMC gene expression. Recent studies by Miralles et al29 showed Rho-actin signaling also regulated the subcellular localization of the myocardin-related SRF coactivator MAL or MRTF-A in NIH 3T3 fibroblasts. MRTFA was predominantly localized in the cytoplasm in serum-starved 3T3 cells but accumulated in the nucleus after serum stimulation. Solway and associates have provided very interesting results showing that serum-induced translocation of SRF into the nucleus in cultured tracheal SMC was Rho kinasedependent.28,30 Thus, agonist-induced activation of RhoA and subsequent translocation of SRF and/or myocardin/MRTFs by actin shuttling may play an important role in activation of CArG-dependent SMC genes. Recent work by Kuwahara et al31 showed that both MRTF A and B are shuttled to and from the nucleus by actin treadmilling in the SMC, a mechanism that may couple the contractile apparatus to SMC gene expression.
Thus far, we have discussed the regulation CArG-dependent SMC genes in the context of SRF and myocardin as activators of transcription. However, SMC differentiation genes can be rapidly switched off, an underlying event of phenotypic switching in several vascular diseases. Recent evidence indicates that SMC phenotypic switching results from a combination of loss of activators as well as by stimulation of active suppressor pathways or repressors. For example, Liu et al showed that the Kruppel-like transcription factor KLF4 suppressed SM
-actin promoter activity by interacting with a transforming growth factor-ß control element (TCE) adjacent to CArGB in the SM
-actin promoter.32 Moreover, follow-up studies showed that KLF4 suppressed myocardin and prevented myocardin/SRF from associating with CArG regions in SMC genes.33 There appear, however, to be redundant pathways for transcriptionally repressing SMC genes. For example, there is evidence that PDGF BB-induced suppression of SMC genes also involves SP1,34 competition for myocardin binding to SRF by phosphorylated ELK-1,35 and ets-1.36 Finally, a substantial body of evidence demonstrates that Ca2+-activated transcription factors, such as CREB, play a role in regulating expression of c-fos in SMCs.37 However, their role in regulating SMC-selective gene expression and phenotypic switching is relatively unexplored and thus the remaining topic of discussion in this review.
 |
ET-Coupling in SMCs
|
|---|
Although ET-coupling has been extensively studied in neurons,
immune cells and other cell types, ET-coupling in smooth muscle
is truly in its infancy. A number of recent studies from our
laboratory
26 and others
3739 have begun to establish general
paradigms for ET-coupling in SMCs, including the following:
(1) ET-coupling is highly dependent on precise subcellular control
of Ca
2+ levels; (2) specific excitation signals can selectively
activate distinct transcription factors, eg, NFAT, CREB, and/or
SRF; (3) activation of distinct gene subsets, ie, c-fos and
CArG-dependent SMC genes, can share a common initial excitation
signal but selective secondary activation pathways, eg, CaMK
and RhoA/ROK; and (4) there exist a multitude of potential players
in EC-coupling whose role in ET-coupling have yet to be defined.
Given space constraints, we have chosen to review key studies
that link EC-coupling to ET-coupling, with the final end point
being a
transcriptional event. We believe this is an important
distinction as there are several studies showing that EC-coupling
regulates transcription factors, but
few that reveal a transcriptional
outcome or change in the expression of a specific gene, ie,
ET-coupling.
 |
ET-Coupling: CREB and CaMK
|
|---|
Ca
2+-calmodulin-dependent enzymes are involved in both SMC contraction
and activation of transcription factors. Calmodulin (CaM) is
activated by Ca
2+ to form Ca
2+-CaM, which activates myosin light
chain kinase to phosphorylate the 20 kDa light chain of myosin
and induce contraction. Ca
2+-CaM is also a regulator of the
phosphatase calcineurin, which regulates the transcription factor
NFAT (nuclear factor of activator T-cells), and calciumcalmodulin-dependent
protein kinase (CaMK), which regulates the transcription factor
CREB (cAMP response element binding protein). CREB transcriptional
activation occurs through its binding to the CREB-binding protein
(CBP), a coactivator that links many proteins to transcriptional
machinery or by binding to the Ca
2+/cAMP response element (CRE)
in the promoter enhancer of genes.
40 Of interest, c-fos contains
one CRE element 3' to the CArG element whereas CArG-dependent
SMC differentiation marker genes do not contain consensus CRE
elements. Phosphorylation of CREB (pCREB) at serine 133 enables
CREB to modulate gene transcription through CRE elements.
41 CREB can be phosphorylated not only at serine 133 but also at
serine 142, which is thought to be a negative regulatory site.
42 Phosphorylation of CREB is mediated by various kinases with
the cAMP/PKA pathway being the principle modulator. However,
in the case of Ca
2+-dependent activation, CREB phosphorylation
is thought to be regulated by the following signaling cascade:
Ca
2+ binds to calmodulin (Ca
2+-CaM), Ca
2+-CaM freely diffuses
into the nucleus through the nuclear pore complex and activates
nuclear CaMK, resulting in CREB phosphorylation.
Perhaps the greatest impact and advancements in the field of SMC ET-coupling have been made by seminal studies by Nelson and colleagues, who tested the hypothesis that signals which regulate EC-coupling could translate to ET-coupling in SMCs.37,39,43 They showed that depolarization-induced constriction with 60 mmol/L KCl activated L-type VGCCs and Ca2+ influx resulting in increased pCREB and c-fos expression in pressurized intact cerebral microvessels.37 Moreover, this response was dependent on CaMK activity as deduced using the generic Ca2+-calmodulin kinase inhibitor KN-93, which inhibits CaMKII and CaMKIV. Although these were the first studies to show ET-coupling in SMCs, these results were not initially surprising given that L-type VGCCs mediate CREB phosphorylation and c-fos activation in several excitable cell types, including neurons. However, what was unique about this study is that they further tested whether altering regulation of subsarcolemmal Ca2+ would alter ET-coupling. RyRs on the superficial SR generate Ca2+ sparks, activating BKCa channels, hyperpolarizing the membrane and inactivating L-type VGCCs to limit Ca2+ influx. If L-type VGCCs played the dominant role in regulating ET-coupling of pCREB and c-fos, then inhibiting Ca2+ sparks would favor Ca2+ influx via VGCC and increased ET-coupling. In these studies, blocking ryanodine receptors with ryanodine ablated Ca2+ sparks and increased phosphorylation of CREB and translocation of pCREB to nuclei and c-fos activation, a process that could be prevented by nisoldipine, an L-type VGCC blocker.37
Both native and culture vascular SMCs express CaMKII and CaMKIV.37,44 In SMC tissues and cultured cells, CaMKII is predominantly cytosolic and implicated in the modulation of myosin light chain kinase sensitivity to Ca2+ and in regulation of cell migration, and it is involved in the control of Ca2+ channels, sarcoplasmic reticulum Ca2+-ATPase activity, and MAP kinase activation. In neurons, CaMKIV is thought to be predominantly located in the nucleus and thus may play a role in ET-coupling as opposed to EC-coupling, although there is limited direct support of this in SMCs. The functions of CaMKII and CaMKIV on CREB signaling are opposite. That is, CaMKII phosphorylates CREB on Ser 142 which is a negative regulatory site, whereas CaMKIV phosphorylates CREB at Ser 133, the activation phosphorylation site.42 Thus, it seems likely that activation of nuclear CaMKIV phosphorylates nuclear CREB driving subsequent CRE-dependent transcription of c-fos. However, when nuclear import is blocked in SMCs by inhibiting the RAN GTPase with wheat germ agglutinin or an inactivating Ran mutant (T24N Ran), pCREB accumulated in the cytoplasm after depolarization and increased intracellular Ca2+.43 Interpretation of these results is decidedly complex but suggests that nuclear export of CREB may be required for phosphorylation, which raises new questions regarding the function of CREB export, as it is predominantly localized to the nucleus, and the role of intracellular Ca2+ dynamics in regulating CREB localization.
One interesting issue that arises from these results is whether Ca2+-mediated processes, ie, non-VGCCmediated, can regulate c-fos expression. SOCE (store operated Ca2+ entry) has been observed in SMCs, although in the normal contractile SMC phenotype this observation may be vascular bed and species specific. Studies by Pulver et al39 showed that experimental manipulation of Ca2+ handling in intact cerebral blood vessels to elicit SOCE resulted in increased nuclear accumulation of phosphorylated CREB and c-fos message. This response was independent of L-type VGCCs as nisoldipine did not block the effect. Although the signaling mechanisms/kinases involved in CREB phosphorylation were not explored, it is intriguing to presume that this response is mediated by CaMK. However, although details of this mechanism need to be resolved, what has become apparent is that events like Ca2+"sparks" and SOCE exemplify the localized interrelationship of Ca2+ and intracellular ultrastructure underlying ET-coupling in SMCs in intact blood vessels.
 |
ET-Coupling: NFAT
|
|---|
A very interesting story that has evolved in ET-coupling is
the regulation of the transcription factor NFAT in SMCs. NFAT
represents a family of Ca
2+-dependent transcription factors
comprising four well characterized isoforms, designated NFAT1
(NFATc2/p), NFAT2 (NFATc1/c), NFAT3 (NFATc4), and NFAT4 (NFATc3/x).
45,46 Most NFAT isoforms are constitutively expressed and exist in
the cytsol as transcriptionally inactive phosphoproteins. The
NFATs are activated by calcineurin, a Ca
2+/CaM-dependent, serine/threonine-specific
phosphatase 2B that is activated during EC-/ET-coupling by fluctuations
in myoplasmic Ca
2+. Dephosphorylation of NFAT by calcineurin
unmasks nuclear localization signals and transcriptionally active
NFAT is translocated to the nucleus.
45 Stimuli that provoke
a sustained moderate elevation in global Ca
2+ have consistently
been shown to effectively promote nuclear localization of NFAT
in nonexcitable cells. It has been shown that SMCs express NFAT1,
NFAT2, NFAT3, and NFAT4, although NFAT4 appears to be the predominant
isoform expressed in intact blood vessels.
38 Insight that NFAT
may be regulated in SMCs was first described in the A7r5 aortic
smooth muscle cell line whereby treatment with PDGF-BB induced
transcriptional activation of an NFAT-specific promoter reporter
construct.
47 These studies were extended into intact blood vessels
by Nelson colleagues, and it was shown that PDGF-BB elicited
nuclear translocation of NFAT4 via L-type VGCCs but depolarization
alone, ie, activation of VGCCs, did not result in nuclear tranlocation
of NFAT4, indicating that Ca
2+ influx is necessary but not sufficient.
38 These results are in direct contrast to CREB regulation in which
VGCC activation alone is sufficient to activate CREB and translocate
p-CREB to the nucleus. Moreover, where VGCCs are required for
PDGF-BB-induced translocation of NFAT to the nucleus, PDGF-BB
induced translocation of pCREB does not require VGCCs.
43 Taken
together, these results suggest that specific Ca
2+-dependent
transcription factors are differentially regulated by specific
Ca
2+ signaling pathways. The signaling specificity of Ca
2+-dependent
activation of NFAT4 in SMCs is further refined by the SR. SR
Ca
2+ release is required for NFAT4 dephosphorylation by calcineurin;
however, the mode of SR Ca
2+ release appears to be critical.
That is, activation of NFAT4 by Gq/11-coupled receptors requires
IP3-mediated SR Ca
2+ release and Ca
2+ influx via VGCCs, whereas
Ca
2+ release in the form of sparks by ryanodine receptors in
the SR may exert an inhibitory effect on NFAT4 nuclear accumulation.
38 A proposed role of sparks is to maintain myoplasmic Ca
2+ levels
at low concentrations. As such, these results emphasize the
importance of global increases in Ca
2+ for NFAT4 activation
in SMCs. Of interest, in physiologically pressurized cerebral
arteries (100 mm Hg), NFAT4 is localized to the nucleus and
this response is abrogated by blocking VGCCs.
48
It is clear that NFAT plays some role in SMC development. For example, work by Crabtree and colleagues49 showed that mice with disruptions to the NFAT3 and NFAT4 genes die at embryonic day 11 with a generalized defect in vessel assembly and mice with a mutation to inactivate the calcineurin B gene show a similar phenotype. Further evidence that NFAT can regulate SMC differentiation marker gene expression was shown by Wada et al,50 whereby overexpression of NFAT2 activated the SMMHC promoter through interaction with GATA-6 and pharmacological blockage of calcineurin decreased SMMHC promoter activity. There is a putative NFAT binding site in the SMMHC promoter enhancer (GGAAAA), at 519/514 relative to the transcriptional start site as well as a GATA-6 binding site at 810/805. However, there is no evidence NFAT2 binds to this NFAT cis element in intact chromatin in SMCs nor has it been shown that loss of NFAT2 function results in altered SMMHC promoter activity. Moreover, there is no evidence that ET-coupling plays any role in regulating this process as these studies were performed in unstimulated, quiescent cells. It is likely, however, that NFATs do play a critical role in SMC differentiation and hence expression of SMC differentiation marker genes as overexpression of NFAT2 or calcineurin in a neural crest cell model of SMC differentiation increased the induction of SMC populations as determined by increased cell numbers expressing SMMHC and SM
-actin.51
Although the preceding studies clearly implicate the NFAT family of transcription factors and Ca2+ signaling in SMC differentiation and potentially SMC differentiation marker gene expression, evidence defining the specific ET-coupling pathways that regulate SMC differentiation marker gene expression, both SRF-CArGdependent and CArG-independent genes, at the molecular level is limited (Figure). Of interest, Nelson and colleagues recently published an interesting result suggesting that NFAT4 positively regulates SM
-actin through a NFAT cis element that is very near the intronic CArG of the SM
-actin promoter,52 supporting a role of NFATs in positively regulating SMC phenotype. Although SRF was shown to interact with NFAT4 in vitro, it still remains to be determined whether this interaction exists in vivo in intact chromatin and whether NFAT4 affects activity of the full-length SM
-actin promoter as only a truncated, 56-bp insert containing the NFAT cis element was used in these studies.
 |
ET-Coupling: SMC Differentiation Marker Genes
|
|---|
Although the aforementioned studies defined a fundamental physiological
pathway linking Ca
2+ to c-fos gene expression, eg, VGCC


[Ca
2+]
i
CaMK

P-CREB


c-fos,
very little is known about the role of intercellular Ca
2+ in
mediating changes in the expression of a subset of genes that
typify the differentiated SMC. This distinction is important
in that unlike markers defining the differentiated SMC phenotype,
eg, SM

-actin, SMMHC or SM22

, c-fos is expressed in all cell
types and thus is not a marker for any terminally differentiated
cell. Moreover, the expression patterns of markers that typify
the differentiated SMC can be highly variable because the SMC
is prone to rapid phenotypic switching in response to vascular
injury or pathological stimuli, as previously discussed.
We recently observed that depolarization-induced Ca2+ influx through L-type VGCCs in cultured aortic SMCs resulted in an increase in the mRNA levels of SM
-actin, SMMHC, SM22
.26 VGCC-induced activation of these SMC differentiation marker genes was CArG-dependent and required myocardin as shown by deletion promoter analyses of CArG regions in the SM
-actin promoter and siRNA to myocardin, respectively. VGCC activation also resulted in increased c-fos promoter activity as well as mRNA. These results present a unique dichotomy: How can two disparate gene subsets (SMC differentiation genes versus growth-response/proliferation genes) share a common pathway of activation, VGCC-mediated activation? RhoA/ROK signaling plays an integral role in regulating SRF-dependent activation of CArG-dependent SMC differentiation marker gene expression, but not of c-fos.26 Thus, RhoA/ROK serves as a point of divergence between SMC differentiation marker gene regulation and c-fos gene regulation in VGCC-mediated ET-coupling. Blocking ROK activity with Y27632 prevented VGCC-mediated activation of SM
-actin, SMMHC and SM22
but had no effect on c-fos activation. In contrast, inhibition of CaMKs with KN93 had no effect on VGCC-mediated induction of SM
-actin, SMMHC and SM22
but blocked c-fos induction. Thus, what has evolved from these studies and work by Nelson and colleagues is a signaling pathway whereby ET-coupling via L-type VGCCs selectively regulates myocardin/SRF/CArG-dependent SMC gene expression via RhoA/ROK, whereas CArG-dependent growth response genes, such as c-fos, are regulated by CaMK (Figure). What remains to be determined is whether non-CArGmediated SMC-selective gene expression is regulated by ET-coupling. The non-CArGdependent gene ACLP (aortic-carboxy-like peptidase), which is upregulated by SMCs after vascular injury, is not regulated by VGCCs and RhoA/ROK.26 However, ACLP, unlike SM
-actin and SMMHC, is presumably a marker of the proliferative SMC cell phenotype and hence may be regulated by yet undefined ET-coupling pathways that promote expression of genes that define the synthetic phenotype.53 Moreover, it is not known whether Ca2+ sparks and SOCE, which regulate CREB and c-fos expression, also regulate SRF and CArG-dependent SMC gene expression.
It is interesting to speculate that signals which regulate short term contraction also regulate long term SMC differentiation marker gene expression. As discussed, actin polymerization is critical for SRF and MRTF shuttling to and from the nucleus and likely plays a critical role in CArG-dependent gene regulation.28,30,31 In practice, treatment of SMCs to destabilize actin polymerization would alter contraction, but simultaneously alter actin treadmilling of SRF/MRTF to the nucleus, a process that is required for CArG-dependent SMC gene expression.27 Although contraction and transcription are likely coupled, addressing this experimentally is difficult as uncoupling contraction will undoubtedly require uncoupling the contractile apparatus. In addition, turnover of SMC differentiation marker genes in mature blood vessels is very low, such that normal homeostatic input signals including transient alterations in circulating vasoactive compounds would not be expected to elicit altered transcriptional responses. Rather, it seems more likely that ET-coupling would require either chronic elevations in a humoral factor such as angiotensin II, or alternatively "cellular integration" or "memory." ET-coupling may share common regulatory controls involved in neural control of memory, which include RGS proteins shown to be highly expressed in vascular SMCs, including far higher levels in arteries versus veins.54 There is also the possibility that epigenetic control of chromatin structure contributes to integrative ET-coupling. Our laboratory has provided novel evidence showing that SMCs exhibit unique patterns of histone modifications at gene loci encoding SMC marker genes that not only distinguish them from non-SMCs but which also appear to play a key role in phenotypic switching in response to vascular injury.55 However, as yet, very few studies have directly investigated the role of epigenetic modifications in ET-coupling.
To begin to address these complex issues, we recently developed a unique embryonic stem cell embryoid body (EB) model of SMC differentiation that permits not only isolation of purified populations of fully contractile embryonic stem cell (ESC)-derived SMCs, but also the opportunity to directly dissect the role of specific regulatory genes and pathways in ET-coupling.56,57 For example, using KO embryonic stem cells one can ask not only whether SMC differentiation still occurs within the embryoid body but also whether specific deletion of a gene postulated in EC-/ET-coupling alters SMC gene expression or contractile function. Of major significance, we recently clearly established the validity of this ESC-EB model for predicting SMC phenotypes in vivo in that in collaborative studies with Eric Olsons group we found that myocardin null ESCs were capable of differentiating into SMCs both in the in vitro ESC-EB system as well as in vivo in chimeric KO mice generated by injection of KO ESCs into the inner cell mass of wild type mouse blastocysts.24 Moreover, in separate studies in this system we tested whether L-type VGCCs regulate SMC differentiation marker expression in the 28-day EB.26 Chronic 24-hour exposure of the EB to nifedipine blocked spontaneous contraction of ESC-derived SMC but also suppressed expression of SM
-actin and SMMHC. These findings suggest that basal Ca2+ influx required for phasic contraction is also required to maintain contractile gene expression. However, whether contraction, per se, is required for ET-coupling remains to be determined, as well as whether alterations in chromatin structure contribute to how sustained contractile responses couple to transcriptional regulation of SMC contractile proteins.
One interesting observation from our recent studies was that activation of VGCCs increased myocardin expression in SMCs.26 An insightful commentary on this by Joseph M. Miano59 proposed several vexing questions, a few of which we reiterate and expand on. First, how does membrane depolarization induce myocardin expression? Second, does elevated myocardin expression elicit contraction? That is, is myocardin more than a transcription factor, possibly a protein that interacts with the contractile apparatus? Third, are the two paralogs of myocardin (MRTF-A and MRTF-B) similarly responsive to Ca2+ transients and can they substitute for myocardin in membrane depolarization-induced gene expression? Fourth, what is the mechanism underlying membrane depolarization-induced SRF binding to CArG boxes, how does SRF-myocardin direct increases in CArG-dependent gene expression, does myocardin remodel chromatin as with CBP to increase DNA-binding factor accessibility?
Unfortunately, to date, mechanisms that regulate myocardin expression at the transcriptional level are unknown as the promoter-enhancer for this gene has not been identified and validated for recapitulation of endogenous expression patterns using transgenic mice. Thus, evidence that myocardin is regulated at the transcriptional level is limited to measuring changes in endogenous myocardin mRNA levels. However, depolarization and angiotensin II induce myocardin expression, whereas acute vascular injury suppresses myocardin.19,26,60 In contrast to this limited knowledge, more mechanistic studies have shed insight into how myocardin regulates CArG-dependent SMC gene expression at the chromatin-promoter level. Several findings give insight into how ET-coupling may play a role in this process. First, p300 and CBP (CREB-binding protein), which are among the most characterized histone acetyl-transferases (HATs), are extremely sensitive to changes in nuclear Ca2+61 and have been shown to be involved in the recruitment of transcription factors that regulate muscle contractile protein expression. Second, studies by Qui and Li62 showed that stimulation of the SM22
promoter by the coactivator CBP (CREB-binding protein) was dependent on histone acetyltransferase activity and that CBP binding to intact chromatin was associated with SRF. CBP contains a signal-regulated transcriptional activation domain that is controlled by nuclear calcium and calcium/calmodulin-dependent (CaM) protein kinase IV and by cAMP.63 Third, exciting new work by Olson and colleagues revealed that myocardin induces the acetylation of nucleosomal histones surrounding SRF binding sites (CArG regions) in SMC differentiation marker genes.64 Myocardin HAT activity was dependent on p300 binding to the TAD region (transcriptional activating domain) of myocardin. Thus, although purely speculative at this point, Ca2+-dependent activation of p300 and/or CBP may be involved in regulating myocardin-activated SMC gene expression. However, results by our own group contradict this hypothesis as inhibition of CaMKs in cultured SMCs had no effect on VGCC-mediated activation of myocardin/SRF/CArG-dependent SMC gene expression.26 Thus, future studies are needed to advance our understanding of how myocardin and myocardin induced-activation of CArG-dependent gene expression are regulated by ET-coupling in SMCs by CBP, p300, and HATs in general, as well as other histone modifying enzymes that control chromatin structure and the "permissiveness" of SMC marker gene loci for transcriptional activation.55
 |
ET-Coupling: SMC Phenotypic Switching, IKCa, and TRPC
|
|---|
Thus far we have considered how Ca
2+ influx via VGCC positively
regulates CArG-dependent gene expression, yet also promotes
early growth response gene activation, ie, c-fos. An outstanding
question, however, is whether there are opposing ET-coupling
events that negatively regulate SMC differentiation marker gene
expression, ie, promote SMC phenotypic modulation and suppression
of SMC differentiation marker genes, perhaps in circumstances
such as vascular injury. The most compelling data that such
events exist in response to vascular injury relate to the expression
patterns of intermediate conductance Ca
2+-activated K channels
(IKCa1) and transient receptor potential channels (TRPC), as
discussed previously.
Although mature, quiescent, native arterial SMCs do not typically express IKCa1, Neylon et al65 demonstrated that proliferating rat aortic SMCs had enhanced charybdotoxin-sensitive potassium channels, which they concluded to be IKCa1 channels. In addition, a reciprocal expression between IKCa1 and the BKCa channel has been observed in intimal versus medial SMCs after injury.66 Of particular interest, both restenosis after rat carotid balloon injury66 and SMC proliferation in vitro67 were attenuated with the specific IKCa1 channel blocker, TRAM-34, implicating that functional upregulation of IKCa contributes to SMC proliferation. Increased IKCa expression in proliferating or injured vascular SMCs is due, at least in part, to downregulation of repressor element 1-silencing transcription factor (REST),67 thus providing another transcription factor that may be involved in SMC phenotype modulation. The expression profile of TRP family proteins also varies with SMC phenotype. That is, the potent SMC mitogen PDGF-BB has been shown to upregulate TRPC6,13 and both TRPC1 and TRPC6 are upregulated with an organ culture model of vascular injury.16 The role of TRPC in regulating genes involved in SMC proliferation is intriguing especially given that TRPC-mediated SOCE has been shown to regulate c-fos gene expression in SMCs, as discussed previously.39 Taken together, these studies provide preliminary evidence for a role of IKCa1 and TRPC channels as a regulator of vascular SMC phenotypic modulation. However, it is unknown whether IKCa1 or TRPC channel activity influence cell phenotype by regulating SMC differentiation marker gene expression directly or whether IKCa and TRPC expression are required for SMC proliferation independent of SMC differentiation marker gene expression. It is also unknown whether IKCa and TRPC activation suppress myocardin/MRTFs or activate transcription factor pathways that are involved in directly suppressing CArG-dependent SMC genes. Conversely, it is possible that IKCa and TRPC are upregulated by a common factor, such as PDGF-BB (which suppresses SMC differentiation marker genes), and hence their role is completely independent of regulating SMC differentiation marker gene expression but required for other SMC injury responses, such as migration and or proliferation. Similarly, Miguel-Velado et al recently demonstrated the importance of voltage-dependent K channel (Kv) isoform switching in phenotype remodeling of uterine arterial SMC.68 Taken together, these studies emphasize the complex interaction between specific ion channel expression profiles, Ca signaling, and selective gene expression in SMCs, which will require much more investigation to fully understand.
 |
ET-Coupling: The Nucleus?
|
|---|
An obviously critical issue in consideration of ET-coupling
is how alterations in cytosolic calcium are "transmitted" across
the nuclear membrane, and whether the process involves changes
in nuclear calcium. Thus far, a dominant theme for ET-coupling
is that it is primarily mediated by changes in cytosolic rather
than nuclear calcium, which in turn alters the activity and/or
nuclear-cytoplasmic transport of transcriptional activators
and repressors. However, there is unequivocal evidence in non-SMC
cell types that nuclear Ca
2+ plays a role in the regulation
of Ca
2+-activated transcription factors and gene expression.
61,69,70 One of the most notable examples is the demonstration of the
requirement of nuclear Ca
2+ and cytoplasmic Ca
2+ for CREB-dependent
transcription in neuroblastoma cells. In brief, cells were injected
with dextran-coupled BAPTA, a Ca
2+ buffer that is too large
to pass through nuclear pores and thus can be used to clamp
Ca
2+ independently in the nucleus or cytoplasm.
71 Injection
of dextran-BAPTA into the nucleus prevented CREB phosphorylation,
suggesting that either the kinetics or the amplitude of the
increase in nuclear Ca
2+ is important in CREB activation. Other
results suggest that CREB phosphorylation on SER 133 can also
occur in the absence of elevated cytoplasmic Ca
2+ and nuclear
Ca
2+. Phosphorylation of CREB occurred despite buffering cytoplasmic
Ca
2+ with EGTA, which also prevents elevations in nuclear Ca
2+,
but allows Ca
2+ elevation close to the plasma membrane.
72,73 Taken together, these results imply that a membrane-bound Ca
2+ sensor can activate a signaling pathway that leads to phosphorylation
of CREB, but additional Ca
2+-dependent steps that occur in the
nucleus are required. Two other transcription factors of potential
relevance to ET-coupling in SMCs are NFAT (as discussed) and
Elk-1, an ETS family transcription factor that binds and regulates
SRF in multiple cell types, including SMCs. A decrease in nuclear
Ca
2+ deactivates nuclear calcineurin allowing one of multiple
NFAT kinases to rephosphorylate NFAT, resulting in transport
of pNFAT out of the nucleus and inactivation of NFAT-dependent
transcription.
70,74 Elk-1 phosphorylation and MAPK (mitogen-activated
protein kinase) translocation to the nucleus, which appear to
be required or Elk-1 transcriptional activity, require an increase
in nuclear Ca
2+.
75 Of particular interest, Elk-1 has recently
been shown by Olson and colleagues to displace myocardin from
SRF in response to PDGF-BB signaling,
35 a signaling event that
also activates multiple Ca
2+ events. An important caveat, however,
is that our knowledge of nuclear Ca
2+ regulation and transcriptional
activation described herein is taken solely from studies in
neurons and non-SMCs. Thus, a key question is whether these
results can be extrapolated to ET-coupling in SMCs. Virtually
nothing is known about these mechanisms in SMCs and similar
mechanisms undoubtedly play a role in ET-coupling to SMC gene
expression and specifically CArG-dependent SMC differentiation.
An attractive hypothesis is that Ca
2+ in the nucleus of SMCs
is tightly buffered and regulated similar to Ca
2+ in the subsarcolemmal
space and that this regulation dictates gene regulation in response
to Ca
2+-activated transcription factors. Although limited, there
is evidence that SMC nuclear Ca
2+ regulation can be altered
in response to physiological or pathophysiological stimuli,
eg, vascular disease, such that the amplitude and duration of
nuclear Ca
2+ responses to contractile agonists are severely
altered.
76,77 Whether this alters gene expression remains to
be determined.
 |
Conclusions and Perspectives
|
|---|
In conclusion, mechanisms for ET coupling in vascular SMC, and
regulation of SMC-selective gene expression and phenotype, are
beginning to evolve. The
Figure summarizes major advances thus
far. First, L-type VGCCs differentially regulate SRF/CArG-dependent
SMC differentiation marker gene expression and c-fos gene expression
via RhoA/ROK/myocardin and CaMK, respectively. Second, both
"sparks" (which activate BK
Ca channels) and store-operated Ca
2+ entry (SOCE, likely mediated by TRPC) regulate c-fos expression,
although whether they regulate SMC differentiation marker genes
is unknown. Third, the calcineurin/NFAT axis is tightly regulated
in SMCs yet the precise function of NFAT signaling in regulating
SMC differentiation marker gene expression or growth response
genes is unknown. Fourth, we hypothesize that "proatherogenic"
stimuli, eg, growth factors or hemodynamic forces that promote
SMC phenotypic modulation, upregulate pathways involved in controlling
proliferation or growth response gene expression (IKCa, TRPC,
SOCE) and suppress SMC differentiation marker gene expression
mediated by L-type VGCCs and "sparks," although the latter is
untested (
Figure). Admittedly, we have greatly oversimplified
very complex mechanisms. Several outstanding questions remain.
How do SMCs integrate short-term calcium responses into long
term changes in gene expression and how do these events differ
in various vascular beds, eg, conduit vessels versus microvessels?
Moreover, how do SMCs regulate nuclear Ca
2+ to control Ca
2+-activated
transcription factors? Does Ca
2+ signal to chromatin modifying
enzymes, ie, p300 or CBP, to modify histones and regulate transcription
factor access to genes? Do IKCa and TRPC activation suppress
myocardin/MRTFs or activate transcription factor pathways, eg,
KLF4, that are involved in directly suppressing CArG-dependent
SMC gene? Of course, understanding how ET-coupling operates
in the SMC is only one aspect of the multitude of hemodynamic
and humoral regulated signaling pathways,
cis-regulatory elements
and transcription factors that collaborate to ensure homeostasis
in the SMC. An ultimate goal, therefore, will be to bring to
bear all of the latest technology, including functional genomics
and mouse models of conditional mutagenesis, to understand ET-coupling
in the context of such regulatory networks with the goal of
developing novel ways of manipulating SMC homeostasis in the
face of disease.
 |
Acknowledgments
|
|---|
Funding to B.R.W. to investigate SMC Ca
2+ regulation, SMC gene
transcription, and SMC ET-coupling in health and disease over
the past 8 years was supported by the American Heart Association
(AHA pre-doc with Dr Michael Sturek), American Physiological
Society (post-doc with Dr Gary K. Owens), and the AHA (New Investigator),
respectively. Other support for this work includes NIH HL52490
and HL071574 to Doug Bowles and NIH PO1 HL19242, RO1 HL38854,
and R37 HL57353 to Gary Owens. There are no conflicts of interest
to disclose.
 |
Footnotes
|
|---|
Original received November 3, 2005; revision received February
6, 2006; accepted February 24, 2006.
 |
References
|
|---|
- Owens GK, Kumar MS, Wamhoff BR. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev. 2004; 84: 767801.[Abstract/Free Full Text]
- Yoshida T, Owens GK. Molecular determinants of vascular smooth muscle cell diversity. Circ Res. 2005; 96: 280291.[Abstract/Free Full Text]
- Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev. 2003; 83: 13251358.[Abstract/Free Full Text]